Literature DB >> 14578745

FTY720 does not abrogate acute graft-versus-host disease in the dog leukocyte antigen-nonidentical unrelated canine model.

Richard S Lee1, Christian S Kuhr, George E Sale, Eustacia Zellmer, William J Hogan, Rainer Storb, Marie-Térèse Little.   

Abstract

BACKGROUND: Acute graft-versus-host disease (GVHD) remains a significant impediment to successful hematopoietic stem-cell transplantation (HSCT). Here, we examined the effectiveness of 2-amino-2-(2-[4-octylphenyl]ethyl)-1,3-propanediol hydrochloride (FTY720), an immunosuppressant that retraffics activated lymphocytes to secondary lymphoid organs, for the treatment of acute GVHD in an established dog leukocyte antigen-nonidentical unrelated canine HSCT model.
METHODS: Dogs were given HSCT after conditioning with 920 cGy total body irradiation. The dogs received methotrexate 0.4 mg/kg/day on days 1, 3, 6, and 11 and FTY720 (5 mg/kg/day orally) after developing GVHD.
RESULTS: Five of six dogs achieved engraftment, developed acute GVHD, and were treated with FTY720. FTY720 resulted in a profound decrease in lymphocytes and a temporary mitigation of clinical GVHD; however, GVHD recurred in all dogs. Four of five dogs were euthanized because of severe GVHD and the fifth because of severe inanition associated with moderate GVHD.
CONCLUSIONS: Compared with controls, treatment of GVHD with FTY720 did not control this complication or significantly increase survival.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14578745     DOI: 10.1097/01.TP.0000083891.14089.B8

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

Review 1.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

2.  Short-term KRP203 and posttransplant cyclophosphamide for graft-versus-host disease prophylaxis.

Authors:  Emi Yokoyama; Daigo Hashimoto; Eiko Hayase; Takahide Ara; Reiki Ogasawara; Shuichiro Takahashi; Hiroyuki Ohigashi; Takahiro Tateno; Yuta Hasegawa; Xuanzhong Chen; Takanori Teshima
Journal:  Bone Marrow Transplant       Date:  2019-11-04       Impact factor: 5.483

Review 3.  Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.

Authors:  Leslie S Kean; Laurence A Turka; Bruce R Blazar
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

4.  Identification and characterization of canine dendritic cells generated in vivo.

Authors:  Marco Mielcarek; Kristin A Kucera; Richard Nash; Beverly Torok-Storb; Hilary J McKenna
Journal:  Biol Blood Marrow Transplant       Date:  2007-09-07       Impact factor: 5.742

Review 5.  Acute graft-versus-host disease: from the bench to the bedside.

Authors:  Gerard Socié; Bruce R Blazar
Journal:  Blood       Date:  2009-08-27       Impact factor: 22.113

6.  Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model.

Authors:  M Lupu; R Storb
Journal:  Vet Comp Oncol       Date:  2007-03       Impact factor: 2.613

Review 7.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

Review 8.  Sphingolipid metabolism in T cell responses after allogeneic hematopoietic cell transplantation.

Authors:  Linlu Tian; Besim Ogretmen; Brian Y Chung; Xue-Zhong Yu
Journal:  Front Immunol       Date:  2022-08-16       Impact factor: 8.786

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.